These cancer cells may still produce neoantigens that could be picked up by antigen presenting cells and be cross-presented to CD8+ T cells, but the primed and activated CD8+ TILs are unable to engage these cancer cells due to the absence of the MHC Class I. In this situation, the immune system has to rely on cell types other than T cells to engage cancer cells that do not express MHC Class I molecules. Here, CD8A is linked to cancer.